Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma

Canadian Journal of Physiology and Pharmacology

Volumn 84, Issue 10, 2006, Pages 1121-1128

  Lambert, Bieke ^a   De Ridder, Leo ^b   De Vos, Filip ^b   Slegers, Guido ^b   De Gelder, Virginie ^b   Van De Wiele, Christophe ^a   Thierens, Hubert ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Dose rate; Hepatocellular carcinoma; Rhenium 188

Indexed keywords

COBALT 60; CYTOTOXIC AGENT; FLUOROURACIL; GEMCITABINE; RHENIUM 188; TOPOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; COBALT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUCOSE TRANSPORTER 1; RHENIUM; SLC2A1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; COBALT THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; GAMMA RADIATION; GENETICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COBALT RADIOISOTOPES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUOROURACIL; GAMMA RAYS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; RHENIUM; TOPOTECAN;

EID: 33846954419     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y06-055     Document Type: Article

References (34)

1. Abrams, R.A., Pajak, T.F., Haulk, T.L., Asbell, S.O., 1998. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins oncology center. Cancer J. Sci. Am. 4: 178-184.
2. Aguayo, A., and Patt, Y.Z. 2001. Non surgical treatment of hepatocellular carcinoma. Semin. Oncol. 28: 503-513. doi:10.1016/S0093-7754(01)90143-5.
3. Boschi, A., Uccelli, L., Duatti, A., Colamussi, .P, Cittantii, C., Filice, A., et al. 2004. A kit formulation for the preparation of 188Re-Lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl. Med. Commun. 25: 691-699.
4. Brans, B., Van Laere, K., Gemmel, F., Defreyne, L., Vanlangenhove, P., Troisi, R., et al. 2002. Combining iodine-131 Lipiodol therapy with low dose cisplatin as a radiosensitizer: preliminary results in hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 29: 928-932.
5. Castañeda, F., and Kinne, R.K. 2000. Short exposure to millimolar concentrations of ethanol induces cell death in multicellular HepG2 spheroids. J. Cancer Res. Clin. Oncol. 126: 305-310.
6. Chen, Y., and Okunieff, P. 2004. Radiation and third-generation chemotherapy. Hematol. Oncol. Clin. North Am. 18: 55-80. doi:10.1016/S0889-8588(03)00145-X.
7. Chenoufi, N., Raoul, J.L., Lescoat, G., Brissot, P., and Bourguet, P. 1998. In vitro demonstration of synergy between radionuclide and chemotherapy. J. Nucl. Med. 39: 900-903.
8. Hall, E.J. 1994. Radiobiology for the radiologist. J.B. Lipincott Company, Philadelphia.
9. Ho, S., Lau, W.Y., Leung, T.W., and Johnson, P.J. 1998. Internal radiation therapy for patients with primary or metastatic hepatic cancer. Cancer, 83: 1894-1907. doi:10.1002/(SICI)1097-0142(19981101)83: 9∠1894::AID-CNCR4〉3.0.CO;2-O.
10. Kashef, E., and Roberts, J.P. 2001. Transplantation for hepatocellular carcinoma. Semin. Oncol. 28: 497-502. doi:10.1016/S0093-7754(01)90142-3.
11. Lambert, B., De Ridder, L., Slegers, G., De Gelder, V., Dierckx, R.A., and Thierens, H. 2004. Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma. Can. J. Physiol. Pharmacol. 82: 146-152. doi:10.1139/y04-008.
12. Lawrence, T.S., Eisbruch, A., and Shewach, D.S. 1997. Gemcitabine-mediated radiosensitization. Semin. Oncol. 24: S724-S728.
13. Leung, T.W., and Johnson, P.J. 2001. Systemic therapy for hepatocellular carinoma. Semin. Oncol. 28: 514-520. doi:10.1016/S0093-7754(01)90144-7.
14. Llovet, J.M., Real, M.I., Montana, X., Planas, R., Coll, S., Aponte, J., et al. 2002. Arterial embolisation or chemo-embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma. A randomised controlled trial. Lancet, 359: 1734-1739. doi:10.1016/S0140-6736(02) 08649-X.
15. Maeda, H. 2001. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46: 169-185. doi:10.1016/S0169-409X(00)00134-4.
16. Monto, A., and Wright, T.L. 2001. The Epidemiology and prevention of hepatocellular carcinoma. Semin. Oncol. 28: 441-449. doi:10.1016/S0093- 7754(01)90137-X.
17. Murtha, A.D. 2000. Radiobiology of low-dose-rate radiation relevant to radioimmunotherapy. Cancer Biother. Radiopharm. 15: 7-14.
18. Novell, J.R., and Hilson, A.J. 1994. Iodine-131-lipiodol for hepatocellular carcinoma: the benefits of targeting. J. Nucl. Med. 35: 1318-1320.
19. Pawlik, T.M., and Keyomarsi, K. 2004. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59: 928-942. doi:10.1016/j.ijrobp.2004.03.005.
20. Qian, J., Feng, G.S., and Vogl, T. 2003. Combined interventional therapies of hepatocellular carcinoma. World J. Gastroenterol. 9: 1885-1891.
21. Raoul, J.L., Guyader, D., Bretagne, J.F., Heautot, J.F., Duvauferrier, R., Bourguet, P., et al. 1997. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-I-iodized oil in the treatment of hepatocellular carcinoma. Hepatology, 26: 1156-1161.
22. Reidy, D.L., and Schwartz, J.D. 2004. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs, 15: 427-437.
23. Roffler, S.R., Chan, J., and Yeh, M.Y. 1994. Potentiation of radioimmunotherapy by inhibition of Topoisomerase I. Cancer Res. 54: 1276-1285.
24. Santini, M.T., Rainaldi, G., and Indovina, P.L. 1999. Multicellular tumor spheroids in radiation biology. Int. J. Radiat. Biol. 75: 787-799.
25. Schafer, D.F and Sorrell, M.D. Hepatocellular carcinoma. 1999. Lancet, 353: 1253-1257.
26. Seong, J., Kim, S.H., and Suh, C.O. 2001. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. J. Gastroenterol. Hepatol. 16: 883-889.
27. Sundram, F., Chau, T.C., Onkhuudai, P., Bernal, P., and Padhy, A.K. 2004. Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 31: 250-257. doi:10.1007/s00259-003-1363-2.
28. Sutherland, R.M. 1988. Cell and environment interactions in tumor microregions. The multicellular spheroid model. Science (Washington, D.C.), 240: 177-184.
29. Ulrich-Pur, H., Kornek, G.V., Fiebiger, W., Schull, B., Raderer, M., and Scheithauer, W. 2001. Treatment of advanced hepatocellular carcinoma with bi-weekly high-dose gemcitabine. Oncology, 60: 312-315.
30. United Nations Scientific Committee on the Effects of Atomic Radiation. 2000. Combined effects of radiation and other agents. In UNSCEAR 2000 Report. United Nations, New York.
31. Wall, J.G., Benedetti, J.K., O'Rourke, M.A., Natale, R.B., and Macdonald, J.S. 1997. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest. New Drugs, 15: 257-260. doi:10.1023/A:1005851804533.
32. Yang, T.S., Lin, Y.C., Chen, Y.S., Wang, H.M., and Wang, C.H. 2000. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 89: 750-756. doi:10.1002/1097-0142(20000815)89:4〈750::AID- CNCR5〉3.0.CO;2-R.
33. Yi, S.W., Kim, Y.H., Kwon, I.C., Chung, J.W., Park, J.H., Choi, Y.W., et al. 1998. Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolisation. J. Controlled Release, 50: 135-143. doi:10.1016/S0168-3659(97)00127-2.
34. Yoon, C.J., Chung, J.W., Park, J.H., Yoon, Y.H., Lee, J.W., Jeong, S.Y., et al. 2003. Transcatheter arterial chemoembolisation with paclitaxel-lipiodol solution in rabbit VX liver tumor. Radiology, 229: 126-131.